Efficacy Study of Botox for Depression
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this proposed study is to obtain data on the efficacy of Botox in reducing symptoms of MDD in male and female patients between the ages of 18 and 65 years old.
The secondary object is to visually assess each patient's frown before and after the Botox injection to determine if there is a correlation between changes in the frown and changes in mood. The patients will be photographed at screening, visit 2 and 3. Their frown lines will be compared to determine if there is a visible improvement in the frown lines corresponding to an improvement in the efficacy rating scores.
| Condition | Intervention | Phase |
|---|---|---|
|
Major Depression |
Drug: Botox Drug: Saline Solution |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) |
- MADRS [ Time Frame: Patients will be followed for up to 10 weeks ] [ Designated as safety issue: No ]Efficacy will be assessed using: the Montgomery-Asberg Depression Rating Scale (MADRS) screening, visit 2 and discontinuation
- Beck Depression Inventory [ Time Frame: Patients will be followed for up to 10 weeks ] [ Designated as safety issue: No ]Efficacy will be assessed using the patient-rated Beck Depression Inventory II (BDI) at screening, visit 2 and discontinuation.
- CGI-I [ Time Frame: Patients will be followed for up to 10 weeks ] [ Designated as safety issue: No ]Efficacy will be assessed using the Clinical Global Impression-Improvement (CGI-I) at visit 2 and discontinuation
| Estimated Enrollment: | 60 |
| Study Start Date: | February 2011 |
| Estimated Study Completion Date: | June 2012 |
| Estimated Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Botox
The study will be divided randomly into two groups of equal number; one arm will receive a Botox injection; the other will receive saline solution injection
|
Drug: Botox
Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
|
|
Placebo Comparator: Saline Solution
A saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
|
Drug: Saline Solution
29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:• Written informed consent is obtained;
- They are a 18 to 65 years old;
- They meet DSM-IV criteria for MDD as diagnosed by the MINI at screening, and, their current episode must be at least one month in length;
- They have a MADRS score of ≥ 26 at screening;
- They have ≥ 4 on the CGI-S at screening
- Women of childbearing potential (WOCBP) are on an acceptable form of birth control and are not pregnant or lactating;
- They are judged by the investigator to have the capacity to understand the nature of the study;
- They are willing to comply with all the requirements of the study.
- They are considered by the investigator to be likely to adhere to the protocol.
Exclusion Criteria:• They have been treated with botulinum toxin A in the 12 months prior to screening;
- They have another Axis I disorder as a principal diagnosis in the 6 months prior to screening;
- They have a history of substance abuse or dependency in the 2 months prior to screening (recreational use of illicit drugs may be permissible, at the discretion of the investigator);
- They test positive for illicit drugs on urine drug screen, and this has not been adequately explained to the satisfaction of the investigator;
- They endorse MADRS item 10 (suicidal ideas) at a level of 5 or more or have attempted suicide in the six months prior to screening;
- They are considered to be at a significant risk of committing homicide;
- They have an unstable medical condition;
- Women of childbearing potential (WOCBP) who are pregnant or are considering becoming pregnant during the length of the study;
- They are regarded, for any reason by the principal investigator as being an unsuitable candidate for the protocol.
- There has been a change in their medication or psychotherapy treatment regimen in the month preceding screening;
- They have proved to be refractory to three or more adequate antidepressant treatments with methods that have different mechanisms of action.
Contacts and Locations| United States, Maryland | |
| Chevy Chase Cosmetic Center | |
| Chevy Chase, Maryland, United States, 20815 | |
| Capital Clinical Research Associates, LLC | |
| Rockville, Maryland, United States, 20852 | |
| Principal Investigator: | Joshua Z Rosenthal, MD | Capital Clinical Research Association |
More Information
No publications provided
| Responsible Party: | Capital Clinical Research Associates, LLC |
| ClinicalTrials.gov Identifier: | NCT01556971 History of Changes |
| Other Study ID Numbers: | Botox 5515 |
| Study First Received: | March 15, 2012 |
| Last Updated: | March 15, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Depressive Disorder, Major Behavioral Symptoms Mood Disorders Mental Disorders |
Botulinum Toxins, Type A Neuromuscular Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013